Dhanapriya J, Dineshkumar T, Gopalakrishnan N, Sakthirajan R, Balasubramaniyan T
Department of Nephrology, Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu, India.
Indian J Nephrol. 2016 Sep;26(5):347-351. doi: 10.4103/0971-4065.167283.
The incidence of focal segmental glomerulosclerosis (FSGS) is approximately 10% in children <6 years, 20% in adolescents, and 20-25% in adults. A retrospective observational study was done to document clinicopathological correlation, treatment response, and risk factors in the progression of chronic kidney disease (CKD) of primary FSGS in adults and adolescents. A total of 170 patients were studied with a mean follow-up of 4.32 ± 1.2 years. FSGS not otherwise specified was the most common subtype (56%) followed by tip variant (24%). About 32% had complete remission (CR) at a mean time of 6.4 months, 23% had partial remission (PR) at a mean time of 5.7 months, and 45% had no response to steroids. Persistent nephrotic proteinuria at 3 and 6 month and presence of interstitial fibrosis and tubular atrophy >30% in renal biopsy are the independent predictors of poor response to treatment. Presence of anemia, interstitial fibrosis, and tubular atrophy of >30% in renal biopsy and the absence of remission after treatment were the independent predictors of CKD progression. Overall renal survival was 78% at 3 years and 54% at 5 years. Renal survival difference with or without nephrotic proteinuria at onset was 39% and 69% at 5 years. Renal survival was higher in patients with normal renal function (66%) compared with those who had renal failure (42%) at 5 years. Renal survival at 5 years for CR was 69%, PR was 49%, and no remission was 42%.
局灶节段性肾小球硬化(FSGS)的发病率在6岁以下儿童中约为10%,在青少年中为20%,在成年人中为20 - 25%。一项回顾性观察研究旨在记录成人和青少年原发性FSGS慢性肾脏病(CKD)进展中的临床病理相关性、治疗反应及危险因素。共研究了170例患者,平均随访时间为4.32±1.2年。未另作说明的FSGS是最常见的亚型(56%),其次是顶端变异型(24%)。约32%的患者在平均6.4个月时达到完全缓解(CR),23%的患者在平均5.7个月时达到部分缓解(PR),45%的患者对类固醇无反应。治疗3个月和6个月时持续性肾病性蛋白尿以及肾活检中存在>30%的间质纤维化和肾小管萎缩是治疗反应不佳的独立预测因素。肾活检中存在贫血、间质纤维化和>30%的肾小管萎缩以及治疗后未缓解是CKD进展的独立预测因素。3年时总体肾脏生存率为78%,5年时为54%。起病时有无肾病性蛋白尿的患者5年肾脏生存率差异分别为39%和69%。5年时肾功能正常患者的肾脏生存率较高(66%),而肾衰竭患者为42%。达到CR的患者5年肾脏生存率为69%,PR为49%,未缓解者为42%。